0.5241
+0.0401
+(8.28%)
As of 10:15:40 AM EDT. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
7,566
7,566
5,124
9,032
12,000
Cost of Revenue
2,740
2,740
746
725
--
Gross Profit
4,826
4,826
4,378
8,307
12,000
Operating Expense
70,662
70,662
67,600
29,603
42,908
Operating Income
-65,836
-65,836
-63,222
-21,296
-30,908
Net Non Operating Interest Income Expense
-7,995
-7,995
-1,222
-1,696
-4,172
Other Income Expense
-2,748
-2,748
-2,551
-1,495
--
Pretax Income
-76,579
-76,579
-66,995
-24,487
-35,080
Net Income Common Stockholders
-76,579
-76,579
-66,995
-24,487
-35,080
Diluted NI Available to Com Stockholders
-76,579
-76,579
-66,995
-24,487
-35,080
Basic EPS
-1.84
-1.48
-1.48
-0.72
-1.30
Diluted EPS
-1.84
-1.48
-1.48
-0.72
-1.30
Basic Average Shares
46,528.9380
51,808.2280
45,342.4510
34,163.4370
27,044.4620
Diluted Average Shares
46,528.9380
51,808.2280
45,342.4510
34,163.4370
27,044.4620
Total Operating Income as Reported
-65,919
-65,919
-65,759
-21,296
-30,908
Total Expenses
73,402
73,402
68,346
30,328
42,908
Net Income from Continuing & Discontinued Operation
-76,579
-76,579
-66,995
-24,487
-35,080
Normalized Income
-73,848
-73,848
-64,458
-23,050
-35,080
Interest Income
1,417
1,417
2,740
476
123
Interest Expense
9,412
9,412
3,962
2,172
4,295
Net Interest Income
-7,995
-7,995
-1,222
-1,696
-4,172
EBIT
-67,167
-67,167
-63,033
-22,315
-30,785
EBITDA
-65,898
-65,898
-62,197
-21,597
-30,313
Reconciled Cost of Revenue
2,740
2,740
746
725
--
Reconciled Depreciation
1,269
1,269
836
718
472
Net Income from Continuing Operation Net Minority Interest
-76,579
-76,579
-66,995
-24,487
-35,080
Total Unusual Items Excluding Goodwill
-2,731
-2,731
-2,537
-1,437
--
Total Unusual Items
-2,731
-2,731
-2,537
-1,437
--
Normalized EBITDA
-63,167
-63,167
-59,660
-20,160
-30,313
12/31/2021 - 6/15/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
IMAB I-Mab
0.7520
+12.68%
TSHA Taysha Gene Therapies, Inc.
1.2700
+2.01%
MRUS Merus N.V.
41.69
-0.67%
TRVI Trevi Therapeutics, Inc.
5.69
+2.34%
ALXO ALX Oncology Holdings Inc.
0.5035
+2.76%
CNTA Centessa Pharmaceuticals plc
11.80
+1.99%
NGNE Neurogene Inc.
10.82
-1.64%
VERA Vera Therapeutics, Inc.
22.45
+0.10%
SRRK Scholar Rock Holding Corporation
29.15
+4.11%
LXEO Lexeo Therapeutics, Inc.
2.0350
+2.78%